@prefix biolink: . @prefix dcterms: . @prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { biolink:category biolink:Disease . sub:association rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement; rdfs:label "Currently, no medication has been approved for use in the USA for cognition in DLB but there is class I evidence suggesting that donepezil and rivastigmine improve cognition and global function [13, 14•]."; biolink:association_type biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; biolink:has_population_context sub:cohort; biolink:provided_by ; biolink:publications ; biolink:relation nkg:OffLabelIndication . sub:cohort rdfs:label "Elderly"; biolink:category biolink:Cohort . biolink:category biolink:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "WqjzRbyC01YFYEAk/VJBdJxCRrsXA6/bClPNuQuXoKRtuQF9+KtvN7FxEK0l7wCPWCQgwuGCpF3RZajHl51kWj0Hsx44UvjU9gsJ65rEo5JBKH3VI3nbVRsbWCxGYw/DguVr44N5j+UerMvUXDUrBsQ/o8qlq5QV1rVQ9frPE2I="; npx:hasSignatureTarget this: . this: dcterms:created "2021-05-19T12:17:52.029+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-7641-6446; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }